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This study describes the screening of 13 commercially-available plant extracts for 27 
pharmacological activity modulating vascular function using an endothelial cell 28 
model.  A French maritime pine bark extract (FMPBE) was found to have the 29 
greatest effect upon nitric oxide availability in control (181% ± 36% of untreated 30 
cells) and dysfunctional cells (132% ± 8% of untreated control cells).  In healthy 31 
volunteers, the FMPBE increased plasma nitrite concentrations 8 h post-32 
consumption compared to baseline (baseline corrected median 1.71 ± 0.38 (25% 33 
IQR) and 4.76 (75% IQR) µM, p<0.05).  This was followed by a placebo-controlled, 34 
healthy volunteer study, which showed no effects on plasma nitrite.  It was confirmed 35 
that different batches of extract had been used in the healthy volunteer studies, and 36 
this second batch lacked bioactivity, assessed using the in vitro model.  No 37 
difference in plasma catechin levels was seen at 8 h following supplementation 38 
between the studies (252 ± 194 nM versus 50 ±64 nM, p>0.05), however HPLC-UV 39 
fingerprinting showed that the new batch had a 5-15% in major constituents 40 
(including procyanidins A2, B1 and B2) compared to the original batch.  This 41 
research describes a robust mechanism for screening bioactive extracts for vascular 42 
effects.  It also highlights batch variability as a significant limitation when using 43 
complex extracts for pharmacological activity, and suggests the use of in vitro 44 
systems as a tool to identify this problem in future studies. 45 
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1. INTRODUCTION 49 
Plant extracts are a popular potential source of therapeutic interventions for chronic 50 
diseases such as hypertension, due to a range of factors including accessibility, low 51 
toxicity/high tolerance, and user perceptions regarding benefits and ethics of use 52 
(Sauer & Plauth 2017).  Of those plant extracts shown to have beneficial effects on 53 
blood flow and blood pressure in humans, many are rich in polyphenols (e.g. 54 
quercetin, epicatechin), which have been shown to exert positive effects on blood 55 
flow and blood pressure in human volunteers (Schroeter et al 2006, Edwards et al 56 
2007). Thus, there is interest in identifying either isolated polyphenols or extracts rich 57 
in certain polyphenols for use as supplements with health benefits.  The major 58 
limiting factors for studies using plant extracts are i) their poor/inadequate 59 
characterisation, ii) the limited bioavailability of constituents, iii) the properties and 60 
nature of the active component, which may be a metabolic derivative of another 61 
component in the extract before ingestion and, iv) limited knowledge of the 62 
mechanisms that explain any reported bio-active effects (Manach et al., 2005).  It is 63 
also anecdotally described that an additional limitation of the use of crude plant 64 
extracts is the substantial batch-to-batch variability which forms a significant barrier 65 
to the use of crude extracts for therapeutic benefit.  Despite the evidence of potential 66 
batch variation in extract composition, there is little published evidence on this type 67 
of variability in the bioactivity of commercially sourced and partially characterised 68 
extracts.   69 
Therefore, in the present study, we employed a comprehensive experimental 70 
approach to assess the bioactivity of partially-characterised, commercially sourced 71 
plant extracts (i.e. some of the polyphenolic content of these extracts have been 72 
identified). We initially screened polyphenol-rich commercial preparations for 73 
bioactivity (modulation of nitic oxide availability and Angiotensin Converting Enzyme 74 
(ACE) activity) in vascular endothelial cells under both healthy and dysfunctional 75 
conditions at physiologically-relevant concentrations.  Commercially available 76 
extracts were purposefully used in this study, as they are at least partially 77 
characterised (i.e., several polyphenolic species are listed on the certificate of 78 
analysis and extracts are reported to have amounts of these species within defined 79 
ranges) in order to address potential issues with extract characterisation.  Based on 80 
the results of this in vitro screening, a French maritime pine bark extract was 81 
selected for assessment in healthy volunteers.  In order to assess the bioactivity of 82 
this extract in vivo, we undertook , two trials in healthy volunteers; the first study 83 
aimed to provide initial validation of the findings of the in vitro screening results (does 84 
the selected extract demonstrate bioactivity in vivo as well as in vitro?).  The second 85 
study aimed to confirm these findings in a more robust manner, using a placebo-86 
controlled, cross-over design.  87 
2. MATERIALS AND METHODS 88 
Materials 89 
All materials, unless otherwise stated, were purchased from Sigma-Aldrich (Poole, 90 
UK). The following commercially available polyphenol-rich preparations (termed NP 91 
– native preparations) were used in this study, and kindly provided by Boots 92 
Pharmaceuticals: NP1 – Amlamax Indian gooseberry (Emblica officinalis) extract 93 
15% (Arjuna Natural Extracts LTD, India, lot# AET-301/1207/RD-11); NP2 –Black 94 
currant 25% anthrocyanins 82001 Ribes nigrum (Frutarom, Belgum, lot # PB0306) ; 95 
NP3 – Vineatrol 30 grapevine shoot (Vitis vinifera) extract (Breko GMBH, Bremmen, 96 
Germany, lot# R283-12); NP4 – Naturex cocoa 45% PE (Gee Lawson, London, UK, 97 
Lot #V163/016/A12) ; NP5 – Naturex grape skin extract (Gee Lawson, London, UK, 98 
Lot # A101/060/A12); NP6 – Naturex green tea extract (Gee Lawson, London, UK, 99 
Lot # A30/026/A12) ; NP7 – Oligopin French maritime pine bark extract (DRT, 100 
France); NP8 – Mirtoselect bilberry extract 35% (Indena SAS, France, Lot # 101 
30392/M1) ; NP9 – Vinitrox apple and grape polyphenol extract (Nexira, France, lot# 102 
1203297)  ; NP10 - OliOla olive extract (Nexira, France, lot#1112092); NP11 – 103 
Green tea extract  (Slater and Frith, Norwich, UK, Lot# PBH43782); NP12 – 104 
Worldway soy isoflavones (WorldWay Inc., China, Lot# PBH43594) ; NP13 – 105 
Fruitflow lycopene-free tomato concentrate (DSM Nutritional Products, Basel, 106 
Switzerland, powder format, lot# CH2012.01C). 107 
Human umbilical vein endothelial cell (HUVEC) culture 108 
HUVEC were cultured and treated as described by Jones et al 2016.  Briefly, 109 
HUVEC were purchased from Promocell (Heidlberg, Germany) and cultured in 110 
endothelial cell growth media (Promocell, Heidlberg, Germany) supplemented with 111 
20% fetal bovine serum (FBS) and grown up to passage 6 for use in experiments.  112 
Cells were seeded at a density of 14700 cells/cm2 and cultured to a density of 80% 113 
confluency before incubation in serum deprived M199 media (0.5% v/v FBS) 24 h 114 
before experiments.  In order to generate the healthy and dysfunction models, the 115 
cell media was changed to medium-199 supplemented with 0.5% FBS containing 116 
either water (solvent control) or 100 nM angiotensin II  for 8 h.  This treatment has 117 
been shown to reduce nitric oxide bioavailability in HUVEC cultures, providing a 118 
useful model system for assessing the pharmacological effects of polyphenols in 119 
vitro (Jones et al 2016). 120 
Standardisation of polyphenol-rich preparations using the Folin-Ciocalteu assay 121 
All preparations were dissolved in dimethyl-formamide (DMF) at a concentration of 122 
50 mg/ml, using vigorous vortex mixing and centrifugation to remove any precipitate 123 
and debris with the supernatant retained (16000 x g, 5 min, room temperature).  124 
These preparations were further diluted 100-fold in 18.2 MΩ water prior to use in the 125 
assay.  The diluted NP samples (15 µl) were added to 18.2 MΩ water (170 µl), Folin-126 
Ciocalteu reagent (12 µl) and sodium carbonate (200 g/L, 30 µl) in a 96-well plate 127 
and incubated at room temperature for 1 hour in the dark.  Water (18.2 MΩ, 73 µl) 128 
was added to each well and the absorbance at 765 nm was measured using a 129 
BMGlabtech Omega plate reader.  Quantification of phenolic content was done using 130 
a standard curve of epicatechin ranging from 0-200 µM, with the solvent 131 
concentration matched to that of the NP samples.  All samples were assessed in 132 
triplicate, with mean concentrations (relative to epicatechin) calculated. 133 
MTS assay 134 
HUVEC were seeded in 96-well plates as described above, and incubated with 10 135 
µM of each preparation for 8 h.  The cells were then assayed for viability using the 136 
MTS assay kit (Promega, Hampshire, UK) as instructed by the manufacturer. 137 
 138 
 139 
Nitric oxide bioavailability assay 140 
Nitric oxide bioavailability was assessed in HUVEC cultures as previously described 141 
by Jones et al (2016) using the fluorescent probe DAF-2DA (Enzo life-sciences, 142 
Exeter, UK).  Briefly, HUVEC were exposed to the polyphenol-rich extracts at a 143 
standardised concentration of 1 µM (DMF final concentration of 0.1% v/v) for 8 h 144 
prior to assay.  Cells were then washed in HBSS (containing calcium and 145 
magnesium) and incubated with 2 µM DAF-2DA, with fluorescence measured every 146 
minute for 30 minutes at λex = 485 nm and λem = 520 nm (Tecan infinite X200 plate 147 
reader, 10 flashes per point, 4 x 4 grid per well, manual gain = 100).  The linear rate 148 
of fluorescence for each well was calculated and expressed as a percentage of 149 
solvent only control cells. 150 
Initial assessment of bioactivity of French maritime pine bark extract in human 151 
volunteers for validation of in vitro screening results. 152 
The first healthy volunteer study aimed to assess potential bioactivity of the French 153 
maritime pine bark extract (Oligopin®). According to the manufacturer certificate of 154 
analysis, this extract has a high content of low molecular weight procyanidins and <1% 155 
content in tannins. Thirteen healthy volunteers (7 males and 6 females) were screened 156 
after identification from the local research database of healthy volunteers (Academic 157 
Diabetes, Endocrinology and Metabolism Unit, Hull University Teaching Hospitals 158 
NHS Trust).  Inclusion and exclusion criteria are listed in table 1.  One individual was 159 
excluded from participation during screening due to difficult venous access. Thus, a 160 
total of 12 subjects were entered into the clinical study. All the study procedures were 161 
approved by National Research Ethics Services Committee, Yorkshire and the 162 
Humber (14/YH/0084). Written informed consent was obtained from all participants 163 
prior to their commencement in the study.   164 
Participants attended an initial preliminary visit to establish that the inclusion criteria 165 
were met and a single study visit following an overnight fast.  Participant age, gender, 166 
blood pressure, height, weight and body mass index (BMI) from this preliminary visit 167 
are presented in table 2. Participants were instructed by a registered dietitian on how 168 
to follow a polyphenol low diet for one week before starting the trial and for the duration 169 
of the trial. In addition, participants avoided alcohol for 24 hours before attending the 170 
laboratory. Body weight, height, blood pressure, heart rate, temperature, hip and waist 171 
circumference were measured. Baseline blood samples were collected prior to 172 
consumption of the French maritime pine bark extract (Oligopin®, 1.1.g contained in 173 
4 capsules) with ab libitum water. Blood samples were collected at 0 and 30 minutes 174 
and 1, 2, 4 and 8 hours post-ingestion and analysed for plasma nitrate and nitrite 175 
concentrations and for plasma catechin and epicatechin concentrations (see below). 176 
A placebo-controlled assessment of the bioactivity of French maritime pine bark 177 
extract in healthy volunteers. 178 
Twenty-four healthy volunteers (11 males and 13 females, age: 36 ±14 years; BMI: 179 
26.2 ± 3.1 kg/m2) were screened initially after identification from the local research 180 
database of healthy volunteers (Academic Diabetes, Endocrinology and Metabolism 181 
Unit, Hull University Teaching Hospitals NHS Trust). Three subjects dropped out from 182 
the study before (n=1) or after (n=2) entering the intervention phase without giving any 183 
reasons and therefore, replaced by three healthy volunteers from the healthy 184 
volunteers dataset. In total, twenty-four subjects (11 males and 13 females) entered 185 
the study. This study was approved by the National Research Ethics Services 186 
Committee, Yorkshire and Humber (14/YH/0084) and written informed consent was 187 
obtained. The inclusion/exclusion criteria are listed in table 1. 188 
Participants attended five study visits (Visits 1-5). During Visit 1, participants were 189 
screened against inclusion and exclusion criteria by medical history and clinical 190 
examination, routine blood tests (i.e., full blood count, liver function tests, biochemical 191 
profile, clotting screen and a pregnancy test, if applicable) and anthropometric 192 
measurements (see table 3). Similar to the procedure followed in the initial healthy 193 
volunteer study, participants were instructed to follow a low-polyphenol diet throughout 194 
the study and avoid alcohol for 24 hours before attending the laboratory for the main 195 
experimental visits (visit 2-5). An independent person not involved in the study 196 
oversaw participant randomisation using a computer generated randomisation list, and 197 
they un-blinded the samples at the end of the study. The visit 2 and 4 were the 198 
intervention visits when participants consumed the French maritime pine bark extract 199 
(Oligopin®, 1.1.g contained in 4 capsules) or placebo (methylcellulose-filled capsules, 200 
1.1 g contained in 4 capsules) as a first intervention in a randomised order. These 201 
visits were followed by visit 3 and 5 the following mornings (24h following visit 2 and 202 
visit 4, respectively).  Figure 1 shows a flow diagram schematic of this volunteer trial. 203 
Blood samples were collected at baseline following an overnight fast and at 2, 4, 8 and 204 
24h (visit 3 & 5 - following an overnight fast) post-ingestion of French maritime pine 205 
bark and placebo, and were analysed for nitrate and nitrite concentrations.  A washout 206 
period of at least 7 days was used between each intervention, as it was expected that 207 
any bioactive constituents would have been excreted within this time-frame, and cross-208 
contamination between the placebo and French maritime pine bark extract would be 209 
minimised.  210 
Nitrate and Nitrite quantification in human plasma 211 
For the first healthy volunteer study, nitrate and nitrite levels in human plasma were 212 
measured using the Cayman Chemicals colourmetric Nitrate/Nitrite assay kit 213 
(Cambridge Biosciences, Cambridgeshire, UK), as directed by the manufacturer 214 
after filtration of plasma samples using 10 kDa molecular weight cut off filters 215 
(Millipore).  It was noted during the analysis of plasma nitrite levels in the first 216 
volunteer study that the colourmetric assay kit lacked the necessary sensitivity nitrite 217 
detection in our hands.  Thus, in the second healthy volunteer study, the Cayman 218 
Chemicals Fluorometric Nitrate/Nitrite assay kit (Cambridge Biosciences, 219 
Cambridgeshire, UK) was used as directed by the manufacturer, after filtration as 220 
described above. Absorbance and fluorescence measures were undertaken using a 221 
BMGlabtech omega series multimodal plate reader at the wavelengths 222 
recommended by the assay kit manufacturer. 223 
Human plasma catechin and epicatechin measurements 224 
Commercial preparations of French Maritime pine bark are rich in polyphenols and 225 
more specifically, procyanidins, with the main constituents being catechin and 226 
epicatechin. Other active ingredients include polyphenolic monomers, phenocarbonic 227 
acids and their glycosides (Rohdewald, 2002).  Plasma concentrations of catechin and 228 
epicatechin were quantified using a LC-MS approach, using diadzein as an internal 229 
standard.  Plasma samples (200 µl) were incubated with a deconjugation mix (60 µl 230 
sulfatase, 5.1µl β-glucuronidase and 1 µM final concentration of diadzein as an internal 231 
standard) for 2 hours at 37 °C.  These samples were then deproteinated by addition 232 
of 120 µl of acidified DMF (100 µl of DMF plus 20 µl of formic acid) and incubation at 233 
room temperature for 10 minutes with regular mixing by vortex.  The precipitated 234 
protein was removed by centrifugation (16000 x g, 10 minutes) and the supernatant 235 
was retained.  The supernatant was loaded into a HPLC insert vial and analysed as 236 
detailed below. 237 
Chromatographic separation was achieved using a Shimadzu LC20-AD quaternary 238 
pump, SIL-20A HT autosampler and CTO-10A column oven connected via a FCV-239 
20AH2 switching valve to a LC2020 single quadropole mass spectrometer.  An Agilent 240 
Eclipse-XDB-C18 column (5 µm pore size, 4.6 x 150 mm, Agilent Technologies, 241 
Cheshire, UK) was used for separating the analytes as detailed below, with solvent A 242 
comprising of 0.5% v/v formic acid in water, and solvent B comprising 0.5% v/v formic 243 
acid in methanol.  The column was maintained at 40 °C.  The method began with a 244 
gradient of solvent B from 35% to 45% over 5 minutes, followed by an increase in 245 
solvent B from 45% to 80% over 5 minutes.  Solvent B was then maintained at 80% 246 
for 5 minutes before returning to 35% over 30 seconds.  The initial starting conditions 247 
were re-equillabrated over 4.5 minutes.  Under these conditions catechin eluted at RT 248 
= 3.7 min, epicatechin eluted at RT = 4.7 min, and diadzein at RT = 12.6 minutes.  249 
Both catechin and epicatechin were detected at a m\z = 289, diadzein at m\z = 253.  250 
Standard curves of catechin and epicatechin were prepared in plasma from fasted 251 
individuals, shown not to contain these analytes, for the quantification of the samples 252 
collected in this study.  A representative chromatogram and standard curve for each 253 
analyte are shown in Figure 2.  This method showed quantification of both catechin 254 
and epicatechin at a concentration of 100 nM in plasma samples. 255 
 256 
HPLC-UV fingerprinting analysis of French maritime pine bark extracts 257 
The two batches of Oligopin French maritime pine bark extract were assessed for 258 
differences in composition using a HPLC-UV method, with absorbance measured at 259 
280 nm for each extract.  Both extracts were standardised to a concentration of 5 260 
mg/ml of extract in 10% v/v/ dimethyl-formamide (DMF).  A solvent control (10% v/v 261 
DMF) was also assessed at both wavelengths using the method described below.  262 
Standards of procyanidin A2, B1, B2 and C1 (Cambridge Biosciences, Cambridgshire, 263 
UK) were also run at a concentration of 0.1 mM in 10% DMF. 264 
Separation was achieved using a Shimadzu LC20 HPLC system (autosampler, 265 
quaternary pump, column oven, and diode array detector) at a flow rate of 1 ml/min 266 
and an injection volume of 15 µl.  An Agilent Eclipse-XDB-C18 column (5 µm pore size, 267 
4.6 x 150 mm, Agilent Technologies, Cheshire, UK) was used for separating the 268 
analytes as detailed below, with solvent A comprising of 0.1% v/v formic acid in water, 269 
and solvent B comprising 0.1% v/v formic acid in methanol.  The column was 270 
maintained at 40 °C.  The method began with a plateau of solvent B at 2% for 12 271 
minutes, followed by an increase in solvent B from 2% to 25% over 18 minutes.  272 
Solvent B was then increased over 2 minutes to 38%, and maintained at this 273 
composition for 28 minutes before increasing to 80% over 2 minutes.  These 274 
conditions were maintained for 6 minutes before returning to the initial starting 275 
conditions. 276 
Statistical analysis 277 
Normality of distribution of the data was tested using the Shapiro-Wilk test.  For 278 
parametric data, a t-test (with or without Welch correction) or ANOVA with post-hoc 279 
testing was used as appropriate. If the data was not normally distributed, ANOVA on 280 
ranks with comparisons versus control or baseline samples was done using an 281 
appropriate post-hoc test. The Sigmaplot v.12 and Graphpad Prism v. 8 software were 282 
used to do these statistical tests. 283 
For the second healthy volunteer study a two-way ANOVA with repeated measures 284 
was used to determine the effects of treatment and interaction effects (intervention x 285 
time) for blood pressure, nitrite and nitrate concentrations. Non-normally distributed 286 
data were log-transformed prior to this analysis. Significant main or interaction 287 
effects were followed by Bonferroni’s post-hoc analysis. Statistical significance was 288 
set at p≤ 0.05 and SPSS v.24.0 software was used to perform this analysis.  289 
 290 
3. RESULTS  291 
In vitro screening of polyphenol-rich plant extracts – MTS assay 292 
In order to test the extracts for any toxic effects in cultured cells, the extracts were 293 
incubated for 8 hours with cells at a concentration of 10 µM prior to assessment of 294 
cell viability using the MTS assay.  There were no significant decreases in assay 295 
response observed for any of the tested extracts, suggesting that the extracts are not 296 
toxic at this concentration (Figure 3).   297 
In vitro screening of polyphenol-rich plant extracts – nitric oxide bioavailability 298 
All extracts were screened at a standardised concentration of 1 µM, with an 8 hour 299 
incubation period, in cells that had either been treated with solvent control (Figure 300 
4A) or angiotensin II (Figure 4B, n=2-4 independent experiments per extract, 6 wells 301 
per treatment, per experiment).  At this concentration, with the exception of NP4 and 302 
NP6, all tested extracts returned nitric oxide bioavailability to near control levels in 303 
the angiotensin II-treated cells, whereas only NP1 (121 ± 20%, n=3 independent 304 
experiments), NP5 (121 ± 6%, n=2 independent experiments), NP7 (118 ± 5%, n=2 305 
independent experiments) and NP10 (121 ± 8%, n=2 independent experiments) 306 
appeared to improve nitric oxide availability under control conditions.  Thus NP1, 307 
NP5 and NP7 were taken forward for more detailed dose-response assessment 308 
under both control (Figure 4C and dysfunctional conditions (Figure4D).  The extract 309 
NP10 was discounted at this stage due to a significant lack of solubility in aqueous 310 
media.  Through this dose-response assessment (ranging from 1 nM to 1 µM), the 311 
French maritime pine bark extract (NP7) was observed to be the only preparation to 312 
positively affect nitric oxide availability in both healthy and dysfunctional conditions 313 
(Figure 4C and 4D).    314 
In vivo assessment of the effects of the French maritime pine bark extract in human 315 
volunteers 316 
During this study, no adverse effects of supplementation were reported or observed.  317 
Potential vascular bioactivity was assessed using the measurement of plasma nitrate 318 
and nitrite concentrations.  Although no differences were observed between 319 
baseline, 4 h, and 8 h post ingestion for plasma nitrate (mean ± SD, baseline = 31.35 320 
±11.99 µM, 4 h = 25.32 ±8.47 µM, 8 h = 24.22 ± 9.21 µM, p>0.05, one-way ANOVA), 321 
there was a significant increase in plasma nitrite at 8 h compared to baseline (Table 322 
3: median concentration at 4h relative to baseline = -0.96 ± range of -10.25 to 0.00 323 
µM, median concentration at 8h relative to baseline = 1.71 ± range of -0.19 to 4.79 324 
µM, n=11, Kruskal-Wallis test p<0.001, Dunn’s post-hoc test p<0.05 for 8 h versus 325 
baseline).  This finding prompted a second clinical study to further investigate the 326 
vascular bioactivity of French maritime pine bark extract in healthy volunteers.  In the 327 
placebo-controlled, randomised cross-over design study no effect of French maritime 328 
pine bark extract on plasma nitrite was observed at any time point (placebo (mean ± 329 
SD): 4 hours = 0.04 ± 0.09 µM, 8 hours post = 0.06 ± 0.09 µM; Oligopin: 4 hours = 330 
0.04 ± 0.18 µM, 8 hours post = -0.05 ± 0.17 µM; all values corrected for baseline 331 
concentration, raw data in Table 4)).  After the completion of these healthy volunteer 332 
studies it became apparent that two different batches of French maritime pine bark 333 
had been supplied (one used in the initial in vitro and first healthy volunteer 334 
assessments, and the second in the placebo-controlled study).  This observation led 335 
us to hypothesise that there was a either a compositional difference between the two 336 
batches of extract that underlay the differences in apparent bioactivity, or that the in 337 
vitro screening model used in this study did not reliably predict in vivo bioactivity.  338 
In vitro comparison of French maritime pine bark extracts – nitric oxide bioavailability 339 
We first assessed the validity of the in vitro screening assay by comparing both 340 
extracts for effects on nitric oxide availability using the in vitro endothelial cell culture 341 
model, under control conditions using a dose-response of extract ranging from 1 nM 342 
to 1 µM.  It was found that there was no effect of the second batch (Figure 5, n=2 343 
independent experiments, 6 wells per treatment per experiment).  This lack of 344 
previously observed increase in nitric oxide availability suggested that the in vitro 345 
model reflected in vivo bioactivity, and that a likely explanation for the observed 346 
batch variation was due to compositional differences of the French maritime pine 347 
bark extract. 348 
Assessment of French maritime pine bark extract catechin and epicatechin 349 
concentrations in the extracts used in the healthy volunteer studies 350 
Based on composition information from the manufacturer, catechin and epicatechin 351 
were expected to be the major constituents observed in volunteer plasma samples, 352 
however only catechin was detected by the LC-MS method used in all samples 353 
(epicatechin was only detected in a single sample in the placebo-controlled study).  354 
In the first study, plasma catechin was detected at baseline, with no obvious Cmax, 355 
half-life or elimination of catechin detected, despite a trend of an increase in plasma 356 
catechin concentration at 8 h (Figure 6).  In the second study (placebo-controlled), 357 
an increase in plasma catechin levels was detected at 8 hours post ingestion of 358 
Oligopin® compared to baseline (mean increase of 54 nM ± 64 nM, n=24).  This was 359 
a smaller increase than that observed within the first study (mean increase of 252 360 
nM ±194 nM, n=6), however this difference between the two studies was not 361 
statistically significant (p=0.083, unpaired t-test with Welch correction).  To further 362 
assess the two batches for compositional differences, HPLC-UV fingerprinting of 363 
each batch was undertaken (Figure 7).  It is clear from the 280 nm UV traces that 364 
compositionally there are no obvious differences between the batches, however 365 
there is a noticeable difference in the height of each peak, with greater signal in the 366 
original batch compared to the second batch, suggesting that the second batch 367 
contains a lower amount of constituents compared to the original batch.  The 368 
composition of both batches (based upon comparison with the procyanidin A2, B1, 369 
B2 and C1 standards) are detailed in table 6, and the representative peak areas 370 
showed a 5 to 15% reduction of each major constituent in the new batch compared 371 
with the original batch.  Taken together, the fingerprinting and pharmacokinetic data 372 
suggest that the second batch has some compositional deficiency that underlies its 373 




4. DISCUSSION 378 
In this work, we present the results of the application of a screening workflow from a 379 
primary cell culture model to human volunteers. Specifically, we initially screened 12 380 
commercially available, polyphenol-rich extracts for potential pharmacological effects 381 
using a cell culture model of the vascular endothelium, which has been previously 382 
shown to predict pharmacological activity in vivo (Jones et al 2016). Through this 383 
screening, we identified a potentially bioactive extract, French maritime pine bark 384 
extract (Oligopin), which was further assessed in two separate trials in healthy 385 
volunteers. In these studies, we came across a major challenge of working with crude 386 
plant extracts, namely batch-to-batch variability. The two different batches of the 387 
extract used in the two studies had a similarly characterised composition (based on 388 
manufacturer certificates of analysis and HPLC-UV fingerprint analysis) and resulted 389 
in comparable plasma circulating levels of catechin and epicatechin (two possible 390 
candidate bioactive structures, and major constituents of the extract); however, they 391 
yielded different responses in healthy volunteers. Additionally, when compared using 392 
the in vitro screening tool, the two extract batches showed different pharmacological 393 
properties. As such, our work confirms anecdotally reported batch-to-batch variability 394 
in plant extracts and provides evidence that suggests such variability is due to 395 
composition differences and has significant pharmacological consequences.  396 
Additionally, this also highlights a major challenge that will need to be overcome for 397 
the production of a viable and efficacious plant extract, and will likely involve 398 
substantial standardisation of plant strain, growth conditions, and manufacturing 399 
processes.  400 
There are several key challenges identified within the in vitro research of the 401 
pharmacology of dietary polyphenols and polyphenol-rich preparations.  These 402 
include (i) the inherent limitation related to how well the in vitro model mimics the in 403 
vivo environment, (ii) the consideration of the bioavailability of the test compound(s) 404 
(i.e. are the test compound exposure concentration and duration reflective of the in 405 
vivo ADME (absorption, distribution, metabolism, excretion) processes), (iii) the lack 406 
of reflection of oxidative, conjugative and bacterial metabolism of test compounds, 407 
and (iv) the relevance of testing isolated single chemicals rather than considering of 408 
food matrix effects (i.e. diet derived chemicals are part of a complex mixture of 409 
numerous polyphenols and other species) (Alvia-Galvez et al 2018).  The in vitro 410 
screening model used in this study addresses several, but not all, of these issues.  In 411 
particular, the model system uses well-characterised primary vascular endothelial 412 
cells (HUVEC) and endothelial dysfunction is induced using a physiologically 413 
relevant stimulus, angiotensin II (for a detailed characterisation of this approach 414 
please see Jones et al 2016).  In brief, the application of this model system to 415 
explore the bioactivity of quercetin, demonstrated that the HUVEC model showed 416 
similar healthy/dysfunctional responses to those reported in human patient trials 417 
(Jones et al 2016), indicating that this in vitro system reflects in vivo responses at 418 
least to some extent.  The in vitro screening process also aimed to mimic in vivo 419 
ADME characteristics, exposure times reflecting the pharmacokinetics of major 420 
constituents (as identified from manufacturer certificates of analysis), along with the 421 
application of physiologically-relevant concentrations of test compounds (low 422 
micromolar to nanomolar range).  In order to standardise, directly compare and rank 423 
the concentrations of the tested extracts, we chose to quantify total phenolic content 424 
(using the Folin Colciateu assay, relative to epicatechin) rather than focus on a 425 
single polyphenolic species.  It is also likely that our approach better reflected the 426 
complex nature of the extract. Conversely the focus on a single phenolic species 427 
may have resulted in some skewing of the concentrations of the constituents of the 428 
extract.  The complex nature of the plant extracts used in this study also provided a 429 
degree of realism in terms of the food matrix effect issues as highlighted by Avilia-430 
Galvez et al (2018).  Despite the advantages, our study is is limited by the lack of 431 
integration of human and bacterial metabolic processes.  As highlighted by Avila-432 
Galvez et al (2018) and previously by Jones et al (2016), there is currently a lack of 433 
availability of conjugated metabolites of polyphenols, and also the platforms to 434 
synthesise them.  Thus this limitation could not be overcome in this study.     435 
The top “hit” from our in vitro screen was a French maritime pine bark extract 436 
(Oligopin).  French maritime pine bark extracts have previously been reported to 437 
modulate vascular and cardiovascular function in a range of disease models and 438 
systems, including humans (Liu et al., 2004a; Hosseini et al., 2001, Araghi-Niknam 439 
et al., 2000; Wang et al., 1999, Devarahj et al., 2002, Ohkita et al 2011), although 440 
not all studies have reported bioactive effects (Drieling et al., 2010).  It should also 441 
be noted that these studies utilised different commercial preparations French 442 
maritime pine bark extracts (e.g., Oligopin, Pycnogenol, Flavagenol) in variable 443 
dosages over different study durations and have assessed several endpoints, in a 444 
range of different populations (healthy vs. patients with existing comorbidities). Thus 445 
it is challenging to make direct comparisons between our trials and other published 446 
studies.  We used a relatively large (1.1 g) single acute bolus of French maritime 447 
pine bark extract in two separate healthy volunteer experiments. In the initial human 448 
study we showed that French maritime pine bark extract was active, whereas 449 
bioactivity was absent in our second more comprehensive study in healthy 450 
volunteers.  After the completion of both trials, it became apparent that different 451 
batches of extract were used.  The in vitro screening model confirmed that there 452 
were differences in bioactivity between the two batches of the extract.  This 453 
observation of batch-to-batch variability may well contribute to the inconsistent 454 
reports of bioactivity of French maritime pine bark extract in humans, and, represents 455 
a significant challenge of using complex extracts for therapeutic benefits. To address 456 
this issue, we propose pre-screening of different batches of an extract using an 457 
appropriate in vitro system that has or can be shown to reflect in vivo biology to an 458 
appropriate degree. 459 
In summary, this research describes the use of an in vitro primary cell culture model 460 
of endothelial cell function to identify potentially bioactive plant extracts.  The most 461 
effective “hit” from this screening phase showed initial promise in the modulation of 462 
nitric oxide metabolites, however this observation was not repeatable due to the use 463 
of a different batch of extract for the repeat experiment.  Thus, this research 464 
highlights a significant limitation of using complex plant extracts for pharmacological 465 
effects.  It also suggests a potential route to identify this issue in future studies, the 466 
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Table 1: Inclusion and exclusion criteria for both the initial human trial and the placebo-553 
controlled volunteer trial. 554 
Inclusion criteria Exclusion criteria 
Male or Female subjects between the age of 
18-65 who can speak and understand 
English 
Patients not wishing to allow disclosure to their 
GPs. 
 
 Concomitant medication including herbal 
medicines and food supplements 
 
No concomitant medication including 
herbal medicines and food supplements 
 
Concomitant disease processes 
History of drug/alcohol abuse or Alcohol 
intake within 24 hours of dosing visit (visits 2-
4) 
 
No concomitant disease processes Body Mass Index <21 and > 29kg/m2 
 
 Systolic blood pressure >150 mm Hg and or a 
diastolic pressure>90 mm Hg 
 
Body Mass Index 21- 29 kg/m2 
 
Unable to tolerate polyphenol products or 
adhere to low polyphenol diet 
Systolic blood pressure ≤150 mm Hg and 




Subjects who have given informed consent Subjects not willing or able to fast until 12 
noon (a total of 14 hours). 
 
 Pregnant females or planning to conceive in the 
next 3 months 
  
 Participation in any other study currently or in 









Table 2: Subject Characteristics Screening visit 1 for the initial human volunteer study 562 
Volunteer 
number 
Sex Age  
(y) 




BMI SBP DBP HR 
P001 M 40 1.80 78.7 24.3 107 59 59 
P002 F 18 1.62 73.0 27.8 127 87 92 
P003 M 19 1.72 82.0 27.7 118 69 62 
P004 F 43 1.65 72.0 26.4 107 67 73 
P005 M 30 1.87 99.0 28.3 124 88 84 
P006 F 36 1.58 58.0 23.2 113 69 82 
P007 F 25 1.78 90.2 28.5 140 86 95 
P008 M 21 1.80 75.3 23.2 130 76 55 
P009 M 31 1.78 81.1 25.6 133 81 90 
P010 F 24 1.64 58.9 21.9 107 73 58 
P011 F 35 1.60 56.0 21.9 96 70 68 
P012 M 33 1.86 98.0 28.3 121 72 69 
P013 M 32 1.83 93.7 28.0 99 68 90 
 563 
Abbreviations (Units): Age (years); BMI, body mass index (kg/m2); SBP, systolic blood 564 
pressure in (mmHg); DBP, diastolic blood pressure (mmHg); Weight (Kg); Height (meters); 565 















Table 3 Screening Characteristics for the healthy volunteer, placebo-controlled trial. 581 
Volunteer 
number 
Sex Age  
(y) 




BMI SBP DBP HR 
PS001 F 53 1.62 62.4 23.8 134 83 86 
PS002 F 19 1.62 74.8 28.5 135 85 95 
PS003 M 20 1.72 83.6 28.3 121 73 70 
PS004 M 30 1.69 82 28.7 114 69 77 
PS005 F 30 1.71 61.6 21.1 106 76 60 
PS006 M 18 1.88 86.2 24.4 110 59 60 
PS007 M 38 1.88 92 26.0 110 68 58 
PS008 M 46 1.79 88.9 27.7 130 81 69 
PS009 F 47 1.65 78.2 28.7 138 84 78 
PS010 M 56 1.78 90 28.4 116 86 71 
PS011 F 41 1.7 72 24.9 136 82 78 
PS012 F 55 1.55 58.2 24.2 130 73 58 
PS013 M 41 1.83 81 24.2 120 73 57 
PS014 F 36 1.62 59.6 22.7 122 80 69 
PS015 F 46 1.6 62.1 24.3 130 80 54 
PS016 F 21 1.74 87.5 28.9 118 76 73 
PS017 M 38 1.73 73.8 24.7 102 62 68 
PS018 F 39 1.7 72.4 25.1 122 70 50 
PS019 M 22 1.81 75.4 23.0 124 64 68 
PS020 M 30 1.75 87.9 28.7 116 72 80 
PS021 M 20 1.81 81.2 24.8 128 67 64 
PS022 F 19 1.7 61.6 21.3 122 81 66 
PS023 F 24 1.77 66 21.1 110 73 80 
PS024 F 29 1.64 58 21.6 94 65 60 
PS025 F 62 1.57 65 26.4 138 86 90 
PS026 F 50 1.55 48.9 20.4 110 65 69 
PS027 F 27 1.59 72.6 28.7 136 82 92 
 582 
Abbreviations (Units): Age (years); BMI, body mass index (kg/m2); SBP, systolic blood 583 
pressure in (mmHg); DBP, diastolic blood pressure (mmHg); Weight (Kg); Height (meters); 584 










Table 4: Plasma nitrite concentrations for healthy volunteers given the French maritime pine bark 595 




4 h post ingestion 8 h post ingestion  
001 0.00 1.10 
002 0.00 2.56 
003 -10.25 4.76 
005 0.00 7.32 
006 -4.03 1.46 
007 0.00 4.03 
008 0.00 4.79 
009 -0.96 -0.19 
010 -1.33 0.38 
011 -3.86 1.71 
012 -2.47 0.38 
Median -0.96 1.71 
25% IQR -3.86 0.379 




















Table 5: Plasma nitrite concentrations for healthy volunteers given the French maritime pine bark 617 








4 h post 
ingestion 
8 h post 
ingestion 
4 h post 
ingestion 
8 h post 
ingestion 
PS001 -0.11 -0.10 0.07 0.07 
PS002 0.07 0.07 0.01 0.01 
PS003 0.11 0.08 -0.18 -0.23 
PS004 0.03 0.08 -0.08 -0.24 
PS005 0.04 0.05 0.02 -0.02 
PS006 0.08 0.10 0.06 0.14 
PS007 -0.04 0.00 -0.05 0.05 
PS008 -0.05 -0.05 0.23 0.08 
PS009 0.11 0.15 0.12 0.08 
PS010 0.00 -0.01 -0.06 -0.02 
PS011 0.00 0.00 0.08 0.18 
PS012 0.07 0.12 -0.24 -0.23 
PS013 0.09 0.10 0.00 -0.03 
PS014 0.11 0.14 -0.60 -0.55 
PS015 0.08 0.11 0.20 0.04 
PS016 0.14 0.10 -0.35 -0.37 
PS017 0.06 0.11 0.15 0.13 
PS018 0.03 0.08 -0.15 -0.15 
PS019 0.06 0.06 -0.01 0.04 
PS020 0.02 0.17 -0.08 -0.13 
PS021 -0.12 -0.12 -0.08 -0.10 
PS023 0.25 0.26 -0.11 -0.05 
PS025 -0.12 -0.11 0.09 0.08 
PS027 0.04 -0.01 0.03 0.01 
Mean 0.04 0.06 -0.04 -0.05 










Table 6: Major peak identifications based upon comparisons with procyanidin standards (A2, B1, B2 629 
and C1) for the two different batches of Oligopin French maritime pine bark extract.  A comparison 630 
of the peak areas for these peaks is also prevented to illustrate the reduced levels of major 631 
constituents in the new batch compared to the original screened batch is also shown. 632 
 633 
 Peak area 
Retention time 
(min) 
Peak identity % difference between 
batches (new:original) 
18.03 Unknown 13.25 
18.30 Unknown 5.92 
18.63 B1 9.83 
19.36 Unknown 14.77 
20.23 B2 8.34 







Figure 1:  Flow diagram showing the design of the placebo-controlled, randomised, 640 
cross-over trial. 641 
 642 
 643 
Figure 2:  Representative chromatogram of catechin and epicatechin using the 644 
optimised LC-MS method.  Catechin (retention time = 3.7 min), epicatechin (retention 645 
















Figure 3: Assessment of cell viability after incubation with 10 µM of each plant 662 















Figure 4: In vitro screening of polyphenol-rich plant extracts using a HUVEC culture 678 
system.  (A) The effect of the different plant extracts (NP1-13) on HUVEC cultures 679 
under control conditions.  Black bars indicate cultures without NP incubation (1 µM, 8 680 
h), with nitric oxide availability expressed as a percentage of control cultures.  (B) 681 
The effect of the different plant extracts (NP1-13) on HUVEC cultures under 682 
Angiotensin II treated conditions (100 nM, 8 h).  Black bars indicate cultures without 683 
NP incubation (1 µM, 8 h), with nitric oxide availability expressed as a percentage of 684 
angiotensin II treatment only cultures.  (C) Dose-response curves of NP1, NP5 and 685 
NP7 under control and angiotensin II treated (D) conditions.  Nitric oxide availability 686 
is expressed as percentage of control cells.  The dotted lines in the angiotensin II 687 
plots indicates the percentage of solvent control activity for cells without NP 688 




Figure 5: In vitro assessment of the second batch of French maritime pine bark 693 
extract for its effect on nitric oxide availability in control HUVEC cultures.  Graph 694 
shows mean ± SD for n=2 independent experiments (6 wells per experiment).  In 695 















Figure 6.  Plasma concentrations (nM) of catechin for n=5-6 volunteers from the first 711 
healthy volunteer study.  Graph shows mean ± SD for sampling times up to 8 hours 712 
















Figure 7: HPLC fingerprint assessment of the two batches of French maritime pine 729 
bark extract, and comparison with procyanidin standards (A1, B1, B2 and C1), with 730 
absorbance measured at 280 nm.  (A) Solvent control (10% DMF).  (B) The original 731 
batch of Oligopin used in the in vitro screening process and first healthy volunteer 732 
study.  (C) The fingerprint shown in panel B, focussed upon the time range of 15 to 733 
30 minutes.  (D) The second (new) batch of Oligopin used in the placebo-controlled 734 
healthy volunteer study.  (E) The fingerprint shown in panel D, focussed upon the 735 
time range 15 to 30 minutes.  (F) Representative chromatogram of the separation of 736 
procyanidin standards using the fingerprinting method.  (G) The same fingerprint of 737 
standards as shown in panel F, focussed upon the time range 15 to 30 minutes.  The 738 
identities of the various standards used are indicated on the chromatograms in 739 
panels F and G.   740 
 741 
